

北京大学科研伦理与科研诚信培训第十九期（模块 A）日程

2018 年 9 月 20 日（星期四），时间：下午 01:00 - 04:30

地点：北京大学医学部逸夫教学楼 502

12:40 - 01:00	签到	
01:00 - 02:00	隐私保护：美国 HIPAA 法案的启示	王燕芳
02:00 - 03:00	临床研究注册：注意事项及经验分享	曾琳
03:00 - 03:10	休息	
03:10 - 04:10	欧盟一般数据保护法案（GDPR）的伦理启示	刘瑞爽
04:10 - 04:30	问题与讨论	

The HIPAA Privacy Rule

&

Clinical Research

王燕芳
北京大学临床研究所



CONTENTS

目录

1. What is HIPAA?
2. What was HIPAA created?
3. Whyat dose HIPAA consist of ?
4. Why should I care?
5. Effect on clinical research
6. Implementation at UMHS
7. Private rule & DICOM data transfer

01 What is HIPAA

Introduction

HIPAA : Health Insurance Portability and Accountability Act of 1996 (健康保险流通与责任法案, 1996)

HIPAA是由美国国会颁布的联邦法律，并于1996年由总统签署

作为HIPAA法律的一部分，国会指示美国卫生和人类服务部（DHHS）制定法规，以便：

- 保护患者隐私，

- 保护以电子方式存储和传输的健康信息的安全性

 - 最终的HIPAA隐私规则于2003年4月生效

 - 最终的HIPAA安全规则于2005年4月生效

HIPAA compliance is mandatory

What is HIPAA?

- **H**ealth
- **I**nsurance
- **P**ortability and
- **A**ccountability
- **A**ct

02

**WHY WAS HIPAA
CREATED?**

WHY WAS HIPAA CREATED?

- In 2000, many patients that were newly diagnosed with depression received free samples of anti-depressant medications in their mail.
- This left patients wondering how the pharmaceutical companies were notified of their disease.
- After a long and thorough investigation, the Physician, the Pharmaceutical company and a well-known pharmacy chain were all indicted on breach of confidentiality charges.
- This is one of the many reasons the Federal Government needed to step in and create guidelines to protect patient privacy.

03 What does HIPAA consist of?

What does HIPAA consist of?

1. Standardized Electronic Data Interchange transactions and codes for all covered entities.
2. Standards for security of data systems.
3. Privacy protections for individual health information.
4. Standard national identifiers for health care.

Important HIPAA definitions

- **Privacy** - state of being concealed; secret
- **Confidentiality** – containing private information (Ex. Medical Record).
- **Authorization** – to give permission for; to grant power to.
- **Breach Confidentiality** – to break an agreement, to violate a promise.
- **Disclosure** – means the release, transfer, provision of access to, or divulging of information outside the entity holding the information.
- **Use** – means the sharing, employment, application, utilization, examination, or analysis of individually identifiable information within an entity.

Important HIPAA terminology:

Protected Health Information

Protected Health Information [PHI] – is information that is created or received by a covered entity that:

- Relates to the past, present, or future physical or mental health of an individual.
- Identifies the individual or contains reasonable information that can be used to identify the individual(s).
- Examples of Protected Health Information:
 - Name, address, telephone, fax, email, social security number, medical diagnoses, medical records, account numbers and photographs or images.

Important HIPAA Terminology:

Notice of Privacy Practice

- **Notice of Privacy Practice [NPP]**- a notice given to patients concerning the use and disclosure of their Protected Health Information [PHI]

GENERAL RULES

Notice of Privacy Practices



- ◆ Health care providers and health plans will give out a Notice of Privacy Practices (NPP) that describes how we use and share their PHI, patients' rights regarding PHI, our responsibilities regarding PHI, and who to contact for more information.
- ◆ Click [here](#) to review our NPP.

What are a patient's rights under HIPAA

- Right to written Notice of Privacy Practices [NPP] that informs consumers how Protected Health Information [PHI] will be used and to whom it is disclosed
- Right of timely access to see and copy records for a reasonable fee
- Right to an amendment of records
- Right to restrict access and use
- Right to an accounting of disclosures
- Right to revoke authorization

REGULATIONS THAT PROTECT THESE RIGHTS?

THE JOINT COMMISSION STANDARDS

- Patient's rights:
 - Patients have a right to confidentiality of all information that is provided to the healthcare professional and institution.
 - Health care professionals ensure that patient information is secured at all times and if there are any complaints, those complaints will be resolved in a timely manner.

WHAT ARE THE HIPAA RULES AND REGULATIONS THAT PROTECT THESE RIGHTS?

RESEARCH ACTIVITIES

- **NO ONE** is permitted to use Protected Health Information for research without complying with the new HIPAA requirements.
- These HIPAA requirements are entirely separate from the existing federal human subject research regulations.
 - The Privacy Policies and Procedures do not replace or override other rules or procedures established by the Institutional Review Board [IRB], both must be complied with in order to conduct human research.

04 Why should I care

Why Should I Care?

- The Health Insurance Portability and Accountability Act (HIPAA) is a federal law designed to **improve the efficiency and effectiveness** of the health care system.
- Part of HIPAA directly affects your clinical work and the operations of any facility where you will train.
- Understanding the fundamentals of HIPAA will prepare you to step into training sites with a clear understanding of how to comply **with requirements for respecting the privacy of protected health information (PHI)**.

OUR COMMITMENT TO PRIVACY

- ◆ The **University of Michigan** is committed to protecting the privacy and integrity of our patients' health information. The HIPAA Privacy Rule recognizes the importance and value of this commitment.
- ◆ This session will help us continue to do our part in protecting privacy.



Consequences of Violations

Inappropriate disclosure of confidential information is subject to discipline, up to and including discharge from employment. For licensed professionals, it is also subject to discipline by licensing and credentialing bodies

There are civil and criminal penalties for violations of patient privacy:

- Fines up to \$25,000 for multiple violations of the same standard in a calendar year
- Fines up to \$250,000 and/or imprisonment up to 10 years for deliberate misuses of individually identifiable health information.

Types of Data Protected by HIPAA

- Written documentation and all paper records
- Spoken and verbal information including voice mail messages
- Electronic databases and any electronic information, including research information, containing PHI stored on a computer, smart phone, memory card, USB drive, or other electronic device
- Photographic images
- Audio and Video recordings

The Privacy Rule applies to protected health information (PHI)

Protected health information (PHI) is “identifiable” health information acquired in the course of serving patients.

1. Name
2. Social security number
3. Street and email addresses
4. Employer
5. Telephone and fax numbers
6. Member or account numbers (e.g. medical record number, health plan identification number)
7. Relatives' names
8. Date of service, birth or death
9. Fingerprints, photographs, voice recordings
10. Certificate or license numbers
11. Any other linked number, code, characteristic (e.g. device identifiers, serial numbers)

To De-Identify Patient Information You Must Remove All 18 Identifiers

1. Names
2. Geographic subdivisions smaller than state (address, city, county, zip)
3. All elements of DATES (except year) including DOB, admission, discharge, death, ages over 89, dates indicative of age
4. Telephone, fax, SSN#s, VIN, license plate #s
5. Med record #, account #, health plan beneficiary #
6. Certificate/license #s
7. Email address, IP address, URLs
8. Biometric identifiers, including finger & voice prints
9. Device identifiers and serial numbers
10. Full face photographic and comparable images
11. *Any other unique identifying #, characteristic, or code*

The Privacy Rule: Parents and Minors

HIPAA generally defers to state law concerning the relative rights of parents and minors. In this module, the terms “individual” or “patient” mean:

- Parents and legal guardians may generally exercise the HIPAA rights of their minor children;
- Patients 18 or older, or with emancipated or "mature minor" status, may exercise their own rights under HIPAA.
 - If you are in doubt about a patient’s status or have questions about the legal definition of emancipation or "maturity," check with the agency’s legal counsel.
- A minor patient may exercise HIPAA rights regarding matters involving diagnosis or treatment relating to certain conditions (e.g., sexually transmitted diseases, drug or alcohol dependency, and pregnancy).

PHI and Research

Specific procedures may allow PHI to be used or disclosed for research purposes:

- Records can be de-identification.
- Written authorization may be obtained from the patient for research use or disclosure.
- The Institutional Review Board (IRB) may grant a waiver of written authorization.
- Only data needed to prepare work for research purposes only may be disclosed.
- Special provisions may allow for research using a decedent's PHI.

General Data Disclosures

An agency may use or disclose **demographic information** and the **dates of treatment** for the purpose of raising funds for its own benefit, without an authorization.

- Example: “Between January and June we treated 47 patients under 18, 20% of whom had family incomes under \$25,000 per year.

General Data Disclosures

- An agency must make reasonable efforts to limit protected health information to the minimum necessary to accomplish the intended purpose of uses, disclosures, or requests.

05 Effect on Clinical Research

Clinical Research is Uniquely Affected by the Regulations

There are specific methods that allow PHI to be used or disclosed for research purposes:


- All data are de-identified (according to the specific standards of the Privacy Rule).
- A limited data set is collected and released (according to the specific standards of the Privacy Rule).
- A patient gives a written authorization that his or her data may be used and/or disclosed.
- The Institutional Review Board (IRB) may grant a waiver of written authorization.
- Data are collected for preparatory work for research purposes only (according to the specific standards of the Privacy Rule).
- Special provisions are in place for research on a decedent's PHI.

Notice of a Person's Rights to Control His or Her PHI

An agency must distribute to each patient at the first treatment encounter, and obtain written acknowledgment of receipt of, a “Right to receive Notice of Privacy Practices”:

- Describing how the agency may use and disclose PHI.
- Describing the rights the individual has to control his or her health information.

Impact on Clinical Research



06 Implementation at UMHS

Research

Implementation at UMHS

- ◆ HIPAA allows either an IRB or a “Privacy Board” to grant a “waiver of authorization” for use or disclosure of PHI for research purposes (including creation/maintenance of research databases)
- ◆ At UMHS, the Privacy Board also will assist in other ways, including:
 - ❖ Certifications for reviews preparatory to research
 - ❖ Certifications for research on decedents’ information
 - ❖ Approval of data use agreements
 - ❖ Clearinghouse/expertise on privacy issues relevant to human subjects research projects
- ◆ A privacy board is not authorized to review and approve research under the Common Rule

Research

Implementation at UMHS

- ◆ HIPAA requires covered entities (e.g., UMHHC) to “account” for many research-related disclosures made without patient authorization
- ◆ Exceptions:
 - ◆ internal uses do not need to be tracked
 - ◆ disclosures made through a limited data set with a data use agreement do not need to be tracked
 - ◆ disclosures of “deidentified data” do not need to be tracked (no information listed [HERE](#) included in the data set)
 - ◆ disclosures made in studies involving more than 50 subjects do not need to be tracked *if* we keep a list available of all such studies, including title, PI, and contact information
- ◆ Policies/procedures for accounting are under development

Research

What Does HIPAA Mean for You?

- No PHI in Research
 - If you are conducting a project without use of PHI, HIPAA does not apply but IRBMED's informed consent template must be used for all new projects and scheduled continuation reviews beginning April 1
 - *Caution!*
- If you do a blood test or radiological scan or other procedure only for research purposes, and not related to treatment, the information may not be PHI and your project is not regulated by HIPAA; *but*
- If the test or results information passes through the subject's UM electronic medical record ("EMR") (because the medical record number is used and/or information is derived from and/or posted to the EMR or other clinical information systems), then HIPAA may apply

Research

What Does HIPAA Mean for You?

- Some research-related disclosures are “grandfathered” under HIPAA
 - “Express *legal* permission” (usually written permission) from the individual to use or disclose their PHI for research
 - Written informed consent obtained before April 14, 2003
 - Waiver granted by IRB before April 14, 2003 (but if subject is later consented, consent must be HIPAA-compliant)

Research

Application: Multicenter Trials

Multicenter Trials

- Four ways to share PHI with other centers:
 - Written permission from the subject/patient (authorization)
 - Waiver from IRB or Privacy Board
 - Limited Data Set with Data Use Agreement
 - Deidentified data (nothing on [“PHI” list](#))
- form in advance.

Research

Application: Multicenter Trials

- When we need information from other centers for our own research projects:
 - The updated IRBMED informed consent template is intended to comply with the privacy rule and to allow *any* health care provider or health plan to disclose PHI to us (or UMHHC to disclose PHI to our co-investigators) for research purposes.
 - However, every site may have its own rules and policies.
 - If another site or a sponsor requires an additional form to be signed by your subject, IRBMED must review and approve that

07 DICOM数据的传输

Digital Imaging and Communications in Medicine (DICOM)

- DICOM (Digital Imaging and Communications in Medicine) 即医学数字成像和通信，是医学图像和相关信息的国际标准 (ISO 12052)。它定义了质量能满足临床需要的可用于数据交换的医学图像格式。
- DICOM被广泛应用于放射医疗，心血管成像以及放射诊疗诊断设备 (X射线，CT，核磁共振，超声等)，并且在眼科和牙科等其它医学领域得到越来越深入广泛的应用。在数以万计的在用医学成像设备中，DICOM是部署最为广泛的医疗信息标准之一。当前大约有百亿级符合DICOM标准的医学图像用于临床使用。

关于PHI的传输

- 一些J1项目需要在PUHSC和UM之间以DICOM格式共享数十或数百个放射图像。由于DICOM格式将受保护的健康信息（PHI）嵌入图像文件的元数据中，因此必须具有能够确保正确管理和传输这些图像的解决方案。
- 我们开发了一种高度自动化的解决方案，用于去除大量DICOM图像的识别，加密和传输。除了将文件传输到J1服务器和从J1服务器传输文件以及生成PGP公钥之外，不需要用户干预。

关于PHI的传输

- 一旦发件人将这些图像移动到发件人端（PUHSC或UM）上的JI服务器上的预定义文件夹，我们的程序将找到所有DICOM或压缩的DICOM文件，然后通过删除包含的八个DICOM字段自动取消识别DICOM文件PHI。
- 取消标识的DICOM图像文件将被移动到暂存文件夹。然后，我们的程序将使用接收用户的PGP公钥以批处理模式加密暂存文件夹中的文件。加密的文件放入传输文件夹。
- 使用能够处理PUHSC和UM之间不稳定的互联网连接的现有JI数据共享解决方案，传输文件夹中的文件将每五分钟自动同步到JI服务器（UM或PUHSC）的另一端。传输的文件只能由具有相应PGP私钥的接收器使用。
- 我们期待与JI研究人员合作开发定制解决方案，以满足不同JI项目的独特数据管理和分析需求。

感谢您的聆听

临床研究注册

北医三院临床流行病学研究中心

曾琳

zlwhy@163.com

Outlines

临床试验注册的定义与原因

临床试验注册的历史与现状

临床试验注册的类型

临床试验的注册

临床试验注册的检索

临床试验注册：定义

WHO版:临床试验注册是将试验的**设计方案、组织实施和管理**等相关信息按照**国际公认**的形式刊登在可**公开访问**的网站上。所有的注册网站均需按照**WHO**的标准进行管理。

WHO regards trial registration as the publication of an internationally-agreed set of information about the design, conduct and administration of clinical trials. These details are published on a publicly-accessible website managed by a registry conforming to WHO standards.

为什么要进行临床研究注册

科学意义

- 医学研究者可以在试验的起始阶段就能获得相关试验的重要信息，知道谁在做什么研究，方法如何，避免不必要的重复研究；完善研究的相关内容，确保临床试验的严谨性。

伦理学意义

- 促进试验的规范性；
- 病人志愿参加临床试验，承担了风险和成本，他们有权获得试验结果以及他们为人类健康事业的发展 and 医疗服务决策的制定所作出的贡献
- 赫尔辛基宣言规定，“在第一个主体募集前，每个临床试验都必须在可公开访问的数据库中注册”

为什么要进行临床研究注册

循证医学意义

- 有助于避免选择性发表偏倚，防止未报道阴性结果或结果不明确而误导研究人员作出有偏倚的系统综述，影响临床医疗决策

社会学意义

- 有助于社会公众增进对临床试验的了解，提高公众对临床疗效真实性的认识，有助于提高公众对药品/器械生产企业的信任度

强制性要求

- 法律法规要求； 文章发表要求。

为什么要进行临床研究注册

国际医学期刊编辑委员会（International Committee of Medical Journal Editors, ICME）要求所有临床试验在发表之前必须进行国际注册，否则不予发表试验结果。（2005.9）

临床试验注册的历史

ICMJE INTERNATIONAL COMMITTEE of
MEDICAL JOURNAL EDITORS

国际医学杂志编辑委员会

The ICMJE is a small group of general **medical journal editors and representatives of selected related organizations working together to **improve the quality** of medical science and its reporting. ICMJE meets annually to refine its Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.**

临床试验注册的历史

ICMJE INTERNATIONAL COMMITTEE of
MEDICAL JOURNAL EDITORS

国际医学杂志编辑委员会

Recommendations

Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals*

I. About the Recommendations

A. Purpose of the Recommendations

© 2014, Council of the International Committee of Medical Journal Editors

A. Preparing a Manuscript for Submission to a Medical Journal

1. General Principles

Conflicts of Interest

ICMJE INTERNATIONAL COMMITTEE of
MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

世界卫生组织国际临床试验注册平台

WHO ICTRP

- 在2004年11月于墨西哥的墨西哥市召开的卫生研究部长峰会之后，与会者要求WHO促进 “一个连接国际临床试验登记网络的平台，以确保一个单一的存取点和试验的明确识别” 的建立。
- WHO ICTRP的主要目标就是促进所有临床试验 WHO试验注册数据集 的预期注册以及公众对该信息的可访问性。
- **WHO ICTRP不是临床试验注册中心**

Landmark

ICMJE INTERNATIONAL COMMITTEE of
MEDICAL JOURNAL EDITORS



国际医学杂志编辑委员会（ICMJE）、世界卫生组织以及国家政府组织

支持临床试验注册，
要求临床试验在招募
受试者之前将试验具
体措施向公众开放，
并以此作为允许试验
结果发表的条件。

2004年9月，ICMJE

宣布从2005年7月1日
起，只发表已在公共
临床试验注册机构注
册的临床试验结果报
告。

2004年11月WHO

牵头建立国际临床试
验注册平台
(International Clinical
Trials Registry Platform,
ICTRP)；
为临床试验注册库制
定标准

WHO为临床试验注册库 制定了一系列标准

免费向
公众开放

向所有
注册者开放

由非盈利性
机构负责管理

可以实现
电子检索

包含有效资料
和最少资料等

WHO一级注册机构

- WHO一级注册机构符合内容、质量和有效性、可访问性、唯一标识、技术能力和管理的具体标准。WHO一级注册机构满足ICMJE的要求。

<http://www.who.int/ictrp/network/primary/en/>

中国临床试验注册中心 华西 <http://www.chictr.org/cn/>

目前已完成注册17991项



Primary Registries

[WHO Registry Criteria](#) | [WHO Data Set](#) | [Primary Registries](#) | [Partner Registries](#)

Primary Registries in the WHO Registry Network

Primary Registries in the WHO Registry Network meet [specific criteria](#) for content, quality and validity, accessibility, unique identification, technical capacity and administration. Primary Registries meet the requirements of the [ICMJE](#).

The registries that currently meet these criteria are:

Australian New Zealand Clinical Trials Registry (ANZCTR)	Profile	Website
Brazilian Clinical Trials Registry (ReBec)	Profile	Website
Chinese Clinical Trial Registry (ChiCTR)	Profile	Website
Clinical Research Information Service (CRIS), Republic of Korea	Profile	Website
Clinical Trials Registry - India (CTRI)	Profile	Website
Cuban Public Registry of Clinical Trials (RPCEC)	Profile	Website
EU Clinical Trials Register (EU-CTR)	Profile	Website
German Clinical Trials Register (DRKS)	Profile	Website
Iranian Registry of Clinical Trials (IRCT)	Profile	Website
ISRCTN	Profile	Website
Japan Primary Registries Network (JPRN)	Profile	Website (in Japanese)
		Network members: UMIN CTR JapicCTI JMACCT CTR
Thai Clinical Trials Registry (TCTR)	Profile	Website
The Netherlands National Trial Register (NTR)	Profile	Website
Pan African Clinical Trial Registry (PACTR)	Profile	Website
Peruvian Clinical Trial Registry (REPEC)	Profile	Website
Sri Lanka Clinical Trials Registry (SLCTR)	Profile	Website



中国临床试验注册中心

ChiCTR 中国临床试验注册中心
Chinese Clinical Trial Registry

世界卫生组织国际临床试验注册平台一级注册机构

今天是：2018-06-10 星期日

[网站首页](#) | [ChiCTR简介](#) | [检索入口](#) | [重要文件](#) | [注册指南](#) | [常见问题](#)

<http://www.chictr.org.cn>

[访问网站](#)

世界卫生组织国际临床试验注册平台一级注册机构



检索试验



按国家、省
(市)统计



按疾病代码统
计



按试验实施单
位统计



按试验主办单
位统计



按经费或物资
来源统计



按征募研究对
象情况统计

统计数据

已完成注册 17991

预注册 14036

补注册 3952

治疗性研究 10032

预防性研究 132

诊断试验 847

病因学研究 311

预后研究 194

流行病学研究 298

相关因素研究 1487

观察性研究 4280

临床试验透明化文章

- 世界卫生组织国际临床试验注册平台介绍
- 国际医学期刊编辑委员会关于临床试验注册的声明

·临床试验透明化的里程碑事件

中国临床试验注册中心政策

- 关于免费使用临床试验公共管理平台(ResMan)的公告
- 关于成立中国临床试验注册中心香港中心的公告

- 14 ·关于共享临床试验原始数据(IPD)的公告
- 关于针灸临床试验在针灸临床试验注册中心注册的公告

[更多信息](#)

主要的国际临床试验注册库

- 1 **Clinical Trials注册资料库** (<http://www.clinicaltrials.gov>)
 - 2 **英国国立研究注册库** (BNRR, <http://www.nrr.nhs.uk>)
 - 3 **澳大利亚临床试验注册库** (ACTR, <http://www.actr.org.au/>)
 - 4 **英国当前对照试验注册库** (CCT, <http://www.controlled-trials.com>)
 - 5 **Trials Central注册库** (<http://www.trialscentral.org/>)
 - 6 **英国国际标准随机对照试验号注册库**
(ISRCTN, <http://www.isrctn.org/>)
- **Clinical Trials作为应用最广泛的注册库**

NIH临床试验注册平台

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies ▾

About Studies ▾

Submit Studies ▾

Resources ▾

About Site ▾

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

Explore 275,028 research studies in all 50 states and in 204 countries.

ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

IMPORTANT: Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

Before participating in a study, talk to your health care provider and learn about the [risks](#) and [potential benefits](#).

Find a study (all fields optional)

Status ⓘ

Recruiting and not yet recruiting studies

All studies

Condition or disease ⓘ (For example: breast cancer)

X

Other terms ⓘ (For example: NCT number, drug name, investigator name)

X

Country ⓘ




**Study and Intervention Type
(as of September 17, 2018)**


**Number of Registered Studies and
Percentage of Total**

**Number of Studies With Posted Results and
Percentage of Total*****

Total		284,665	32,653
<u>Interventional</u>		225,986 (79%)	30,756 (94%)
<u>Type of Intervention*</u>	Drug or biologic	131,373	24,475
	Behavioral, other	70,323	5,470
	Surgical procedure	23,997	1,672
	Device**	28,072	3,865
<u>Observational</u>		57,376 (20%)	1,897 (6%)
<u>Expanded Access</u>		506	N/A




- Non-U.S. only (48%)
- U.S. only (35%)
- Both U.S. and non-U.S. (5%)
- Not provided (12%)



- Non-U.S. only (57%)
- U.S. only (38%)
- Both U.S. and non-U.S. (5%)

Number of Registered Studies Over Time
and Some Significant Events (as of September 17, 2018)





Region Name	Number of Studies
World	284,665
East Asia	30,487
China	12,668
Hong Kong	1,711
Korea, Democratic People's Republic of	2
Korea, Republic of	9,407
Mongolia	22
Taiwan	5,617

什么研究要进行研究注册

临床试验是指以人为对象的**前瞻性研究**，预先将受试者或受试人群分配至接受一种或多种**医疗干预**，以评价医疗干预对健康结局的影响。其中“医疗干预”包括但不限于药物、细胞及其他生物制品、外科治疗、放射治疗、医疗器械、行为疗法、治疗过程的改变、预防保健等。其定义包括第1阶段到第4阶段的试验。

——WHO

什么研究要进行研究注册

A clinical trial is a research study in which human volunteers are **assigned to interventions** (for example, a medical product, behavior, or procedure) based on a protocol (or plan) and are then evaluated for effects on biomedical or health outcomes. ClinicalTrials.gov also includes records describing **observational studies** and programs providing access to investigational drugs outside of clinical trials (expanded access).

——clinicaltrials.gov

什么研究要进行研究注册

所有在人体中和采用取自人体的标本进行的研究，包括各种干预措施的疗效和安全性的有对照或无对照试验（如随机对照试验、病例-对照研究、队列研究及非对照研究）、预后研究、病因学研究、和包括各种诊断技术、试剂、设备的诊断性试验，均需注册并公告。

——chiCTR

“与人有关”

什么研究要进行研究注册

- ICMJE requires, and recommends that all medical journal editors require, registration of clinical trials in a public trials **registry at or before the time of first patient enrollment** as a condition of consideration for publication.
- ICMJE defines a clinical trial as any research project that prospectively assigns people or a group of people to an **intervention**, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a **health-related intervention** and a **health outcome**.

——ICMJE

Study and Intervention Type (as of September 17, 2018)		Number of Registered Studies and Percentage of Total	Number of Studies With Posted Results and Percentage of Total***
Total		284,665	32,653
Interventional		225,986 (79%)	29,759 (91%)
Type of Intervention*	Drug or biologic	131,373	
	Behavioral, other	70,323	
	Surgical procedure	23,997	
	Device**	28,072	
Observational		57,376 (20%)	
Expanded Access		506	

统计数据

已完成注册 17991

预注册 14036

补注册 3952

治疗性研究 10032

预防性研究 132

诊断试验 847

病因学研究 311

预后研究 194

流行病学研究 298

相关因素研究 1487

观察性研究 4280

怎样注册

- 华西中心，双语注册。在完成中、英文注册资料的上传后一周内获得注册号，获得注册号后第二周可在WHO ICTRP可检索到已注册试验。
- NIH临床试验注册平台，英语注册。试验方案注册系统（PRS），获得临床试验注册号（NCT），至此，该试验方案才得以成功注册。通过NCT，任何人都可以通过网络直接链接到该试验。Pubmed可查询。（速度较快）

中国临床试验如何注册？



世界卫生组织国际临床试验注册平台一级注册机构

网站首页 | ChiCTR简介 | 检索入口 | 重要文件 | **注册指南** | 常见问题

注册指南

请仔细阅读本指南，如有疑问，请与我们联系（推荐使用电子邮件或QQ）：

官方电子邮件：1193142709@qq.com; chictr@hotmail.com; chictr@edu.scu.cn;

617767@qq.com

QQ: 1193142709

Skype: wutaixiang

电话: 18980604562

请注意：

为了适应注册量快速增加的需要，我们对网站进行了更新，完成了对网站的升级并采用顶级域名：www.chictr.org.cn，每周上传世界卫生组织ICTRP。

所有新注册试验均在新网址www.chictr.org.cn进行，原网址不再进行新的试验注册。

请所有注册均转到新网址www.chictr.org.cn进行。

中国临床试验如何注册？

中、英文双语注册

凡在**中国大陆和台湾**实施的临床试验均需采用中、英文双语注册。来自于香港特别行政区和其他国家实施的临床试验可只采用英语注册。

在完成中、英文注册资料的上传后**15天内**可获得**注册号**，获得**注册号后一周内**（特殊情况除外）可在世界卫生组织国际临床试验注册平台检索入口(WHO ICTRP search portal)**检索到已注册试验**。

临床试验注册的内容(WHO)

(1) 全球唯一试验注册号;

(2) 试验注册日期;

(5) 主办者;

(6) 协办者;

(9) 研究的题目;

(10) 正式的科学题目;

(13) 干预措施;

(14) 纳入、排除标准;

(17) 目标样本量;

(18) 招募情况;

(3) 次级注册号;

(4) 资金来源;

(7) 责任联系人;

(8) 研究联系人;

(11) 伦理许可;

(12) 条件;

(15) 研究类型;

(16) 试验启动日期;

(19) 主要结局;

(20) 关键的次要结局。

临床试验
注册的内容

Why Should I Register and Submit Results?

FDAAA 801 and the Final Rule

How to Apply for an Account

How to Register Your Study

How to Edit Your Study Record

How to Submit Your Results

Frequently Asked Questions

Support Materials

Training Materials

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

Explore 284,665 research studies in all 50 states and in 204 countries.

ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

IMPORTANT: Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

Before participating in a study, talk to your health care provider and learn about the [risks and potential benefits](#).

Find a study (all fields optional)

Status ⓘ

- Recruiting and not yet recruiting
- All studies

Condition or disease ⓘ (For example: breast cancer)

 X

Other terms ⓘ (For example: NCT number, drug name, investigator name)

 X

Country ⓘ


 X

Search

[Advanced Search](#)

临床试验注册基本流程

以
clinicaltrial.gov
为例



临床试验注册要提交的内容

- 项目负责人、funding、研究目的、研究内容、纳入及排除标准、多中心研究中各中心需纳入受试者数量、中心的地点和联系方式、研究终点与观察指标、技术路线、分组及随机化方法、统计方法、知情同意书、伦理委员会批件、研究开始和结束时间等等。

注册信息的更新

- 开始纳入第一例受试者后更新研究实际开始时间。
- 纳入最后一例受试者后更新入组完成时间。
- 完成所有人随访后更新研究完成时间。

提交试验结果

- 统计分析完成后更新主要的统计分析结果。
 - 患者流程图
 - 基线和人口学等特征描述
 - 主要、次要结局指标
 - 不良事件

预注册 VS 补注册

- 《赫尔辛基宣言v.08》要求任何临床试验必须在纳入第一例受试者之前在公共注册机构注册。




预注册

- 免费
- 研究完成1年内提交统计结果


补注册

- 付费（3k）
- 提交研究结果的原始数据
- 临床试验数据库公共管理平台ResMan

临床研究流程的影响



临床研究流程的影响



临床研究注册的检索

ChiCTR

中国临床试验注册中心

Chinese Clinical Trial Registry

世界卫生组织国际临床试验注册平台一级注册机构

今天是：2018-09-19 星期三

网站首页 | ChiCTR简介 | **检索入口** | 重要文件 | 注册指南 | 常见问题

简体中文 | English



检索试验



按国家、省
(市) 统计



按疾病代码统
计



按试验实施单
位统计



按试验主办单
位统计



按经费或物资
来源统计



按征募研究对
象情况统计



按注册状态统
计



按干预措施统
计



按伦理委员会
统计



按研究类型统
计

检索试验

项目筛选条件

注册题目	<input type="text" value="阿司匹林"/>	正式科学名	<input type="text"/>	研究课题代号(代码)	<input type="text"/>
注册状态	<input type="text" value="不限"/>	注册号	<input type="text"/>	在其它机构的注册号	<input type="text"/>
<input type="button" value="筛选结果"/>		<input type="button" value="更多筛选"/>			

共检索到30个符合检索条件的试验。

历史版本	注册号	注册题目	研究类型	注册时间
历史版本	ChiCTR1800017605	基因多态性对氯吡格雷和阿司匹林的影响--基于连续血小板计数检测的病例-对照研究 郑州大学人民医院 (河南省人民医院)	相关因素研究	2018/08/06
历史版本	ChiCTR1800017603	基因多态性对阿司匹林的影响--基于连续血小板计数检测的病例-对照研究 郑州大学人民医院 (河南省人民医院)	相关因素研究	2018/08/06

Example: "Heart attack" AND "Los Angeles"

Search for studies:

Search

[Advanced Search](#) | [Help](#) | [Studies by Topic](#) | [Glossary](#)

[Find Studies](#) ▾

[About Clinical Studies](#) ▾

[Submit Studies](#) ▾

[Resources](#) ▾

[About This Site](#) ▾

[Home](#) > [Find Studies](#) > [Search Results](#)

[Text Size](#) ▾

1450 studies found for: aspirin

[Modify this search](#) | [How to Use Search Results](#)

List

By Topic

On Map

Search Details

+ Show Display Options

 Download

 Subscribe to RSS

Only show open studies

Rank	Status	Study
------	--------	-------

1	Unknown †	Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
---	-----------	--

Condition: Ischemic Stroke

Interventions: Drug: Aspirin; Biological: blood sample

2	Active, not recruiting	Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
---	------------------------	--

Conditions: Asthma, Aspirin-Induced; Aspirin Exacerbated Asthma

Intervention: Drug: Prasugrel

3	Recruiting	Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
---	------------	--

Condition: Premature Birth

Interventions: Drug: Low dose aspirin; Drug: Placebo

临床试验注册的检索

International Clinical Trials Registry Platform (ICTRP)

Welcome to the WHO ICTRP

The mission of the WHO International Clinical Trials Registry Platform is to ensure that a complete view of research is accessible to all those involved in health care decision making. This will improve research transparency and will ultimately strengthen the validity and value of the scientific evidence base.



WHO/P. Viroit



The registration of all interventional trials is a scientific, ethical and moral responsibility.

<http://apps.who.int/trialsearch/>



Example: liver cancer OR breast cancer NOT genetic

Search [Search tips](#)

Search for [clinical trials in children](#)

Without Synonyms

[Phases](#) are

- All
- Phase 0
- Phase 1
- Phase 2
- Phase 3
- Phase 4

Welcome

- The Clinical Trials Search Portal provides access to a central database containing the trial registration data sets provided by the registries listed on the right. It also provides links to the full original records.
- To facilitate the unique identification of trials, the Search Portal bridges (groups together) multiple records about the same trial. [More information](#)
- Please note: This Search Portal is not a clinical trials registry. [How to register a trial](#)
- It is now possible to export the results of the search into XML. [More information](#)
- Crawling the ICTRP database now requires a username/password. To request access to the crawling pages please send an email to ictrpinfo@who.int (*This service is now enabled*)
- A new field called 'Prospective registration' has been added to the ICTRP database, More details about this new field can be found [here](#)

Data Providers

Data sets from [data providers](#) are updated every Friday evening according to the following schedule:
Every week:

- Australian New Zealand Clinical Trials Registry, last data file imported on **10 September 2018**
- Chinese Clinical Trial Registry, last data file imported on **10 September 2018**
- ClinicalTrials.gov, last data file imported on **10 September 2018**
- EU Clinical Trials Register (EU-CTR), last data file imported on **10 September 2018**
- ISRCTN, last data file imported on **10 September 2018**
- The Netherlands National Trial Register, last data file imported on **10 September 2018**

Every 4 weeks:

- Brazilian Clinical Trials Registry (ReBec), last data file imported on **10 September 2018**
- Clinical Trials Registry - India, last data file imported on **11 September 2018**
- Clinical Research Information Service - Republic of Korea, last data file imported on **11 September 2018**
- Cuban Public Registry of Clinical Trials, last data file imported on **27 August 2018**
- German Clinical Trials Register, last data file imported on **27 August 2018**
- Iranian Registry of Clinical Trials, last data file imported on **11 September 2018**
- Japan Primary Registries Network, last data file imported on **10 September 2018**
- Pan African Clinical Trial Registry, last data file imported on **10 September 2018**



World Health
Organization



International Clinical Trials
Registry Platform
Search Portal

Home Advanced Search List By Search Tips UTN ICTRP website Contact us

Back to Search

Export to CSV

Export results to XML

3255 records for 2705 trials found for: aspirin [\(What is this?\)](#)

Show 10 records per page

1 2 3 4 5 6 7 8 9 10 ... >>

Recruitment status	Prospective Registration	Main ID	Public Title	Date of Registration	Results available
Not Recruiting	Yes	CTRI/2018/09/015635	checking the difference between the drugs Fentanyl and Dexmedetomidine by giving in spinal canal by adding to Bupivacaine heavy in lower Limb orthopedic surgery	06-09-2018	
Not recruiting	Yes	NCT03661411	Antiplatelet vs R-TPA for Acute Mild Ischemic Stroke	05/09/2018	
Not Recruiting	Yes	CTRI/2018/09/015585	To study the effects of pregabalin on haemodynamics during laryngoscopic tracheal intubation in patients with controlled hypertension	05-09-2018	
Not Recruiting	No	CTRI/2018/09/015574	Comparison of insertion techniques of air-Q intubating laryngeal airway by fiberoptic bronchoscopic assessment in paediatric patients	04-09-2018	
Recruiting	Yes	NCT03661489	Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective Surgery	03/09/2018	
Not Recruiting	No	JPRN-UMIN000033984	Preventive effect of ecabet sodium on low-dose aspirin-induced small intestinal mucosal injury: A randomized, double-blind, pilot study	01/09/2018	
Not Recruiting	Yes	SLCTR/2018/029	Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (Diversity1)	2018-08-31	
Not Recruiting	Yes	CTRI/2018/08/015535	Observe effect of Dexmedetomidine drug to control vomiting after ear operation.	30-08-2018	
Not Recruiting	Yes	CTRI/2018/08/015513	Comparison of effects of two different doses of a drug in controlling responses to putting tube into windpipe	28-08-2018	
Not recruiting	No	ACTRN12618001451291	Comparison of remifentanyl and alfentanil efficacy in sedation for colonoscopy	28/08/2018	

1 2 3 4 5 6 7 8 9 10 ... >>



谢谢！

曾琳

北京大学第三医院

临床流行病学研究中心

更多临床流行病学相关问题敬请关注

微信公众号：**BYSYRCCE**